非洛地平缓释片治疗慢性心功能不全的临床观察

Efficacy and safety of felodipine in chronic heart failure

目的：评价非洛地平治疗慢性心功能不全的疗效与安全性。方法：采用随机对照的方法,将80例慢性心功能不全患者随机分为对照组与治疗组,对照组以洋地黄、利尿剂及血管紧张素转换酶抑制剂等类药物治疗,治疗组在对照组治疗基础上加用非洛地平缓释片2．5～5．0mg/d。比较两组左室射血分数(LVEF)、左室舒张末期内径(LVDd)、尿常规、电解质、肝肾功能、血压、心率等指标。结果：治疗4周后两组心功能均有显著改善,血压、心率、LVDd降低,LVEF升高,治疗前后比较,有显著性差异(P＜0．05)；与对照组相比治疗组收缩压下降,LVEF升高的幅度更显著(P＜0．01)。两组患者在治疗期间尿常规、电解质及肝肾功能均无明显改变。结论：治疗剂量的非洛地平是治疗慢性心功能不全较为理想的药物。

Objective：To evaluate the clinical effectiveness and safety of felodipine in the treatment of chronic heart failure. Methods： Eighty patients with chronic heart failure were divided into two groups randomly （control and treatment group）. Patients in both groups were treated with digitalis, diuretic and angiotensin-converting enzyme inhibitor and patients in treatment group received additional felodipine. Left ventricular ejection fraction （LVEF）, left ventricular end-diastolic diameter（LVDd）, urine test, serum electrolyte, hepatic and renal function, blood pressure and heart rate were kept under observation. Results： After 4 weeks treatment, blood pressure, heart rate, LVDd were significantly decreased and cardiac function, LVEF significantly increased in both groups （P〈 0.05）. The decrease in systolic pressure and increase in LVEF were more significant in the treatment group than in control group （P〈 0.01）, but there was no significant change in urine test, blood electrolyte, hepatic and renal function. Conclusion： Felodipine at therapeutic dose might be effective and safe for the treatment of chronic heart failure.